Odalović, Strahinja (57218390032)Strahinja (57218390032)OdalovićSobić-Saranović, Dragana (57202567582)Dragana (57202567582)Sobić-SaranovićPavlović, Smiljana (57225355345)Smiljana (57225355345)PavlovićGrozdić, Isidora (37107616900)Isidora (37107616900)GrozdićSaranović, Djordjije (57190117313)Djordjije (57190117313)SaranovićPetrović, Milorad (55989504900)Milorad (55989504900)PetrovićMilovanović, Aleksandar (57213394853)Aleksandar (57213394853)MilovanovićPetrasinović, Zorica (56057995200)Zorica (56057995200)PetrasinovićDjurić-Stefanović, Aleksandra (16021199600)Aleksandra (16021199600)Djurić-StefanovićObradović, Vladimir (7003389726)Vladimir (7003389726)Obradović2025-06-122025-06-122011https://doi.org/10.2298/ACI1104067Ohttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84861218955&doi=10.2298%2fACI1104067O&partnerID=40&md5=23125ac92e9431be35bb80e3ccad8051https://remedy.med.bg.ac.rs/handle/123456789/9858The aim of this study was to present preliminary experience with FDG PET/CT in pediatric oncology patients in National PET Center, Clinical Center of Serbia and to asses its impact on management of malignancies in children. 33 FDG PET/CT scans were performed on 30 pediatric patients. PET/CT imaging was performed for staging the disease, assessing therapy efficacy and diagnosing recurrent or metastatic disease. FDG PET/CT changed the stage of the disease in 60.6% (20/33) of the cases. 14 patients were down-staged after PET/CT, mostly patients with Hodgkin's disease, were in 7/10 cases PET/CT showed no activity in residual masses. Six scans led to upstage of the disease. In three cases PET/CT did not change the stage of disease, but has showed new distant metastases. In conclusion, FDG PET/CT showed important role in managing pediatric patients with different malignancies and was useful complementary diagnostic tool to conventional imaging methods.